Lack of antagonism between abacavir, lamivudine, and tenofovir against wild-type and drug-resistant HIV-1.

Lanier ER; Hazen R; Ross L; Freeman A; Harvey R

首页> 外文期刊>JAIDS: Journal of acquired immune deficiency syndromes >Lack of antagonism between abacavir, lamivudine, and tenofovir against wild-type and drug-resistant HIV-1.

【24h】

Lack of antagonism between abacavir, lamivudine, and tenofovir against wild-type and drug-resistant HIV-1.

机译：阿巴卡韦，拉米夫定和替诺福韦之间缺乏对抗野生型和耐药HIV-1的拮抗作用。

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Potential contributors to the high rate of virologic failure observed for tenofovir, abacavir, and lamivudine include a low genetic barrier to resistance for this regimen and antagonistic drug-drug interactions. To examine the second possibility, we tested combinations of abacavir, tenofovir, and lamivudine against wild-type and drug-resistant HIV-1 in vitro using peripheral blood mononuclear cells and MT-4 cells. Antagonistic interactions were not detected for any combination. If the systems examined accurately reflect the in vivo situation, antagonism does not substantially contribute to the poor efficacy of this triple combination.

机译：替诺福韦，阿巴卡韦和拉米夫定观察到较高的病毒学失败率，其潜在原因包括对该方案耐药的低遗传障碍以及药物与药物的相互作用。为了检验第二种可能性，我们使用外周血单核细胞和MT-4细胞在体外测试了阿巴卡韦，替诺福韦和拉米夫定对野生型和耐药HIV-1的组合。没有检测到任何相互作用的拮抗作用。如果检查的系统准确反映了体内情况，则拮抗作用基本上不会导致这种三联组合的不良疗效。

著录项

来源
《JAIDS: Journal of acquired immune deficiency syndromes》 |2005年第5期|共4页
作者
Lanier ER; Hazen R; Ross L; Freeman A; Harvey R;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类内科学;
关键词
Adenine; Anti-HIV Agents; Dideoxynucleosides; HIV-1; Lamivudine; Phosphonic Acids; 腺嘌呤; 抗HIV药; 双去氧核苷类; 拉米夫定; 膦酸类;

机译：Adenine;Anti-HIV Agents;Dideoxynucleosides;HIV-1;Lamivudine;Phosphonic Acids;腺嘌呤;抗HIV药;双去氧核苷类;拉米夫定;膦酸类;

相似文献

外文文献
中文文献
专利

1. Lack of antagonism between abacavir, lamivudine, and tenofovir against wild-type and drug-resistant HIV-1. [J] . Lanier ER, Hazen R, Ross L, JAIDS: Journal of acquired immune deficiency syndromes . 2005,第5期

机译：阿巴卡韦，拉米夫定和替诺福韦之间缺乏对抗野生型和耐药HIV-1的拮抗作用。
2. Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone [J] . José A. Mira12? Luis F. López-Cortés3? Pablo Barreiro4 Cristina Tural5 Manuel Torres-Tortosa6? Ignacio de los Santos Gil7 Patricia Martín-Rico8? María J. Ríos-Villegas9? José Juan Hernández-Burruezo10? Dolores Merino11? Miguel ángel López-Ruz12? Antonio Rivero13? Leopoldo Mu?oz14? Mercedes González-Serrano15? Antonio Collado16? Juan Macías12? Pompeyo Viciana3? Vincent Soriano4 and Juan A. Pineda1? Journal of Antimicrobial Chemotherapy . 2008,第6期

机译：聚乙二醇干扰素联合病毒唑治疗丙型肝炎/丙型肝炎病毒合并感染患者接受阿巴卡韦加拉米夫定或替诺福韦加拉米夫定或恩曲他滨作为核苷类似物骨架的疗效
3. Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. [J] . Mira JA, Lopez Cortes LF, Barreiro P The Journal of Antimicrobial Chemotherapy . 2008,第6期

机译：聚乙二醇干扰素联合利巴韦林治疗HIV /丙型肝炎病毒共感染接受阿巴卡韦加拉米夫定或替诺福韦加拉米夫定或恩曲他滨作为核苷类似物骨架的患者。
4. The Combination of Inhibitors of Lymphocyte Activation Hydroxyurea (HU), Didox (DX), and Trimidox (TX)) in Combination with the Reverse Transcriptase Inhibitors (RTI): Abacavir (ABC), Didanosine (ddI), and Tenofovir (TFV) in the Murine Model of Immun [C] . R. Sumpter, M. Inayat, C. Mayhew International AIDS Conference . 2004

机译：淋巴细胞活化羟基脲（HU），牛（DX）和三苯并（TX）的抑制剂的组合与逆转录酶抑制剂（RTI）组合：ABACAVIR（ABC），脱氨酸（DDI）和替诺福韦（TFV） IMMUN的鼠模型
5. Cost effectiveness analysis of abacavir/lamivudine versus tenofovir/emtricitabine combination therapy as part of highly active antiretroviral therapy in treatment naive HIV-infected patients. [D] . Giguere, Pierre. 2010

机译：阿巴卡韦/拉米夫定与替诺福韦/恩曲他滨联合疗法作为高活性抗逆转录病毒疗法治疗未受HIV感染的患者的成本效益分析。
6. Zidovudine/Lamivudine vs. Abacavir/Lamivudine vs. Tenofovir/Emtricitabine in fixed-dose combinations as initial treatment for HIV patients: a systematic review and network meta-analysis [O] . Juan Carlos Alzate Angel, Marcela María Duque Molina, Héctor Iván García García 2017

机译：齐多夫定/拉米夫定vs.阿巴卡韦/拉米夫定vs.替诺福韦/恩曲他滨作为固定剂量组合用于HIV病人的初始治疗：系统评价和网络荟萃分析
7. Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial [O] . Federico Pulido, Esteban Ribera, María Lagarde, 2017

机译：与Darunavir和Ritonavir Plus Lamivudine与Darunavir和Ritonavir Plus Tenofovir Disoproxil富马特和Emtricyabine或Abacavir和Lamivudine的双重疗法，用于维持人类免疫缺陷病毒1型病毒抑制：随机，开放标签，非流动性Dual-Gesida 8014-Ris- EST45试验

Lack of antagonism between abacavir, lamivudine, and tenofovir against wild-type and drug-resistant HIV-1.

摘要

著录项

相似文献

相关主题

期刊订阅